BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 3546561)

  • 21. Management of breast cancer.
    Cohen IA; Keller JH; Abate MA
    Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical use of aromatase inhibitors in the treatment of advanced breast cancer.
    Trunet PF; Vreeland F; Royce C; Chaudri HA; Cooper J; Bhatnagar AS
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):241-5. PubMed ID: 9365196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
    Smith IE; Harris AL; Morgan M; Gazet JC; McKinna JA
    Cancer Res; 1982 Aug; 42(8 Suppl):3430s-3433s. PubMed ID: 7044525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current status and prospectives of aromatase inhibitors in the treatment of advanced breast cancer].
    Boccardo F
    Minerva Ginecol; 1998 Mar; 50(3):51-63. PubMed ID: 9595916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials.
    Boccardo F; Rubagotti A; Aldrighetti D; Buzzi F; Cruciani G; Farris A; Mustacchi G; Porpiglia M; Schieppati G; Sismondi P
    Cancer; 2007 Mar; 109(6):1060-7. PubMed ID: 17295293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aromatase inhibitors and breast cancer.
    Brodie AM; Njar VC
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):10-20. PubMed ID: 8824460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamoxifen and aminoglutethimide in advanced breast cancer.
    Corkery J; Leonard RC; Henderson IC; Gelman RS; Hourihan J; Ascoli DM; Salhanick HA
    Cancer Res; 1982 Aug; 42(8 Suppl):3409s-3414s. PubMed ID: 7044523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of aromatase activity in human breast cancer.
    Miller WR; Hawkins RA; Forrest AP
    Cancer Res; 1982 Aug; 42(8 Suppl):3365s-3368s. PubMed ID: 7083201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology of aminoglutethimide: structure/activity relationships and receptor interactions.
    Nicholls PJ; Daly MJ; Smith HJ
    Breast Cancer Res Treat; 1986; 7 Suppl():S55-67. PubMed ID: 3755630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aromatase inhibitors as potential cancer chemopreventives.
    Kelloff GJ; Lubet RA; Lieberman R; Eisenhauer K; Steele VE; Crowell JA; Hawk ET; Boone CW; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 1998 Jan; 7(1):65-78. PubMed ID: 9456245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
    Santen RJ; Leszczynski D; Tilson-Mallet N; Feil PD; Wright C; Manni A; Santner SJ
    Ann N Y Acad Sci; 1986; 464():126-37. PubMed ID: 3524346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors.
    Brodie AM; Santen RJ
    Crit Rev Oncol Hematol; 1986; 5(4):361-96. PubMed ID: 3094971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.
    Santen RJ; Worgul TJ; Samojlik E; Interrante A; Boucher AE; Lipton A; Harvey HA; White DS; Smart E; Cox C; Wells SA
    N Engl J Med; 1981 Sep; 305(10):545-51. PubMed ID: 7019703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical use of aromatase inhibitors in the treatment of breast cancers.
    Manni A
    J Cell Biochem Suppl; 1993; 17G():242-6. PubMed ID: 8007705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of aromatase with CGS 16949A in postmenopausal women.
    Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
    J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review.
    Santen RJ
    Breast Cancer Res Treat; 1981; 1(3):183-202. PubMed ID: 6293627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer.
    Lønning PE; Dowsett M; Powles TJ
    J Steroid Biochem; 1990 Mar; 35(3-4):355-66. PubMed ID: 2139151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent progress in development of aromatase inhibitors.
    Santen RJ
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1029-35. PubMed ID: 2149503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology.
    Sasano H; Miki Y; Nagasaki S; Suzuki T
    Pathol Int; 2009 Nov; 59(11):777-89. PubMed ID: 19883428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Growth inhibition of MCF-7 human breast cancer cells by aromatase inhibitors].
    Fukuoka M; Kitawaki J; Yamamoto T; Okada H
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Dec; 43(12):1667-73. PubMed ID: 1836000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.